High Prevalence of OXA-23 Carbapenemase-Producing Proteus mirabilis among Amoxicillin-Clavulanate-Resistant Isolates in France

Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0198321. doi: 10.1128/AAC.01983-21. Epub 2021 Dec 20.

Abstract

In this multicentric study performed in 12 French hospitals, we reported that 26.9% (14/52) of the amoxicillin-clavulanate-resistant Proteus mirabilis isolates produced the OXA-23 carbapenemase. We found that an inhibition zone diameter of <11 mm around the amoxicillin-clavulanate disc was an accurate screening cutoff to detect these OXA-23 producers. We confirmed by whole-genome sequencing that these OXA-23-producers all belonged to the same lineage that has been demonstrated to disseminate OXA-23 or OXA-58 in P. mirabilis.

Keywords: Acinetobacter; OXA-23; Proteae; carbapenemase; epidemiology; infectious clones.

Publication types

  • Multicenter Study

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / pharmacology
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / genetics
  • Microbial Sensitivity Tests
  • Prevalence
  • Proteus mirabilis* / genetics
  • beta-Lactamases* / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Amoxicillin-Potassium Clavulanate Combination
  • beta-Lactamases
  • carbapenemase